ImmunoCAP Allergen f449 – Allergen Component rSes i 1 Sesame seed test

Products are for professional/laboratory use only. ImmunoCAP component from Thermo Fisher – Allergen Component rSes i 1 Sesame seed.

Sesame allergy – a high risk condition

Sesame allergic patients have a high risk of experiencing severe allergic reactions. It has been reported to be even higher than for peanut and tree nut for some allergic patients.^1,2 Sesame allergy is often severe, life-long and co-exists with tree nut allergy.²

Ses i 1 is a major sesame allergen in the 2S albumin seed storage protein group. These proteins are typically heat and digestion stable, and consequently a risk factor for severe reactions in sensitized individuals. Sesame allergy is often severe, life-long and co-exist with tree nut allergy. Among common seeds and nuts​, it has been reported to cause allergic symptoms with the highest severity. Sesame is used in foods as seeds, oil, paste and flour, and is often a hidden allergen, leading to a high risk of accidental intake that may result in severe reactions.

---

---

The new ImmunoCAP Allergen Component test provides:

• Marker for primary sesame allergy with higher clinical specificity than current extract-based tests
• Aid in the diagnosis and management of patients with primary sesame allergy.^3-7
• Help assessing risk for severe events by providing quantitative sIgE levels to Ses i 1.^3-7
• Higher clinical specificity than skin prick test and whole allergen sIgE test with component-resolved diagnostics.^4-7
• First quantitative, CE marked IVD test on the market.

Product description	Article number	Barcode
ImmunoCAP™ Allergen f449, Allergen Component rSes i 1 Sesame seed	PU14610901	E7M

---

---

References

1. Adatia A, Clarke AE, Yanishevsky Y, Ben-Shoshan M. Sesame allergy: current perspectives.
   J Asthma Allergy. 2017;10:141-51.
2. Brough HA, Caubet JC, Mazon A, Haddad D, Bergmann MM, Wassenberg J et al. Defining challenge-proven coexistent nut and sesame seed allergy: A prospective multicenter European study. J Allergy Clin Immunol. 2020;145(4):1231-39.
3. Maruyama N et al. Clin Exp Allergy. 2016;46(1):163-71.
4. Yanagida N et al. J Allergy Clin Immunol Pract. 2019;7(6):2084-86.
5. Saf S et al. J Allergy Clin Immunol Pract. 2020;8(5):1681-88.
6. Goldberg MR et al. Pediatr Allergy Immunol. 2021 May
7. doi: 10.1111/pai.13533. Online ahead of print. 5. Nachshon L et al. J Allergy Clin Immunol Pract. 2019;7:2775-81.